Background-The "topical" eVect of nonsteroidal anti-inflammatory drugs (NSAIDs) seems to be an important cause of NSAID induced gastrointestinal damage. Aim-To examine the possible mechanism of the "topical" phase of damage in the small intestine. Methods-Electron microscopy and subcellular organelle marker enzyme studies were done in rat small intestine after oral administration of indomethacin (doses varied between 5 and 30 mg/kg). The effect of conventional and non-acidic NSAIDs on rat liver mitochondrial respiration was measured in vitro in a Clarke-type oxygen electrode. Results-The subcellular organelle marker enzymes showed mitochondrial and brush border involvement within an hour of indomethacin administration. Electron microscopy showed dose dependent mitochondrial changes following indomethacin administration consistent with uncoupling of oxidative phosphorylation (or inhibition of electron transport) which were indistinguishable from those seen with the uncoupler dinitrophenol. Parenteral indomethacin caused similar changes, but not in rats with ligated bile ducts. A range of NSAIDs, but not paracetamol or non-acidic NSAIDs which have a favourable gastrointestinal tolerability profile, uncoupled oxidative phosphorylation in vitro at micromolar concentrations and inhibited respiration at higher concentrations. In vivo studies with nabumetone and aspirin further suggested that uncoupling or inhibition of electron transport underlies the "topical" phase of NSAID induced damage. Conclusion-Collectively, these studies suggest that NSAID induced changes in mitochondrial energy production may be an important component of the "topical" phase of damage induction.

The objective of this study was to investigate the fate and removal of triclosan (TCS; 5-chloro-2-[2,4-dichloro-phenoxy]-phenol), an antimicrobial agent used in a variety of household and personal-care products, in wastewater treatment systems. This objective was accomplished by monitoring the environmental concentrations of TCS, higher chlorinated derivatives of TCS (4,5-dichloro-2-[2,4-dichloro-phenoxy]-phenol [tetra II]; 5,6-dichloro-2-[2,4-dichloro-phenoxy]-phenol [tetra III]; and 4,5,6-trichloro-2-(2,4-dichloro-phenoxy)-phenol [penta]), and a potential biotransformation by-product of TCS (5-chloro-2-[2,4-dicholoro-phenoxy]-anisole [TCS-OMe]) during wastewater treatment. These analytes were isolated from wastewater by using a C18 solid-phase extraction column and from sludge with supercritical fluid CO2. Once the analytes were isolated, they were derivatized to form trimethylsilylethers before quantitation by gas chromatography-mass spectrometry. Recovery of TCS from laboratory-spiked wastewater samples ranged from 79 to 88% for influent, 36 to 87% for final effluent, and 70 to 109% for primary sludge. Field concentrations of TCS in influent wastewater ranged from 3.8 to 16.6 microg/L and concentrations for final effluent ranged from 0.2 to 2.7 microg/L. Removal of TCS by activated-sludge treatment was approximately 96%, whereas removal by trickling-filter treatment ranged from 58 to 86%. The higher chlorinated tetra-II, tetra-III, and penta closans were below quantitation in all of the final effluent samples, except for one sampling event. Digested sludge concentrations of TCS ranged from 0.5 to 15.6 microg/g (dry wt), where the lowest value was from an aerobic digestion process and the highest value was from an anaerobic digestion process. Analysis of these results suggests that TCS is readily biodegradable under aerobic conditions, but not under anaerobic conditions. The higher chlorinated closans were near or below the limit of quantitation in all of the digested sludge samples. Based on results from this study, the chlorinated analogues and biotransformation by-product of TCS are expected to be very low in receiving waters and sludge-amended soils.

Ageing population and a multitude of neurological and cardiovascular illnesses that cannot be mitigated by medication alone have resulted in a significant growth in the number of patients that require implantable electronic devices. These range from sensors, gastric and cardiac pacemakers, cardioverter defibrillators, to deep brain, nerve, and bone stimulators. Long-term implants present specific engineering challenges, including low energy consumption and stable performance. Resorbable electronics may offer excellent short-term performance without the need for surgical removal. However, most electronic materials have poor bio-and cytocompatibility, resulting in immune reactions and infections. This paper reviews the current situation and highlights challenges for future advancements.

Swift developments in nanotechnology have prominently encouraged innovative discoveries across many fields. Carbon-based nanomaterials have emerged as promising platforms for a broad range of applications due to their unique mechanical, electronic, and biological properties. Carbon nanostructures (CNSs) such as fullerene, carbon nanotubes (CNTs), graphene and diamond-like carbon (DLC) have been demonstrated to have potent broad-spectrum antibacterial activities toward pathogens. In order to ensure the safe and effective integration of these structures as antibacterial agents into biomaterials, the specific mechanisms that govern the antibacterial activity of CNSs need to be understood, yet it is challenging to decouple individual and synergistic contributions of physical, chemical and electrical effects of CNSs on cells. In this article, recent progress in this area is reviewed, with a focus on the interaction between different families of carbon nanostructures and microorganisms to evaluate their bactericidal performance.